The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
New biologicals and biomaterials in the therapy of Alzheimer's disease
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The most well-known genes are those for presenilin-1 (PSEN1), presenilin-2 (PSEN2), and amyloid precursor protein (APP). Mutations in these genes can cause early-onset familial AD, which often manifests before the age of 65 [38].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [38]
Citations
Cites
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Nanogels as Pharmaceutical Carriers: Finite Networks of Infinite Capabilities
Kabanov, A. V., & Vinogradov, S. V. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200900441 · Cited by 1,320
Mitochondria-Targeting Ceria Nanoparticles as Antioxidants for Alzheimer’s Disease
Kwon, H. J., Cha, M.-Y., Kim, D., Kim, D., Soh, M., Shin, K., Hyeon, T., & Mook‐Jung, I. (2016) · ACS Nano · doi:10.1021/acsnano.5b08045 · Cited by 667
Weekley, C. M., & Harris, H. H. (2013) · Chemical Society Reviews · doi:10.1039/c3cs60272a · Cited by 645
Ceria Nanoparticles that can Protect against Ischemic Stroke
Kim, C. K., Kim, T., Choi, I., Soh, M., Kim, D., Kim, Y., Jang, H., Yang, H., Kim, J. Y., Park, H., et al. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203780 · Cited by 592
Tiwari, S. K., Agarwal, S., Seth, B., Yadav, A., Nair, S., Bhatnagar, P., Karmakar, M., Kumari, M., Chauhan, L. K. S., Patel, D. K., et al. (2014) · ACS Nano · doi:10.1021/nn405077y · Cited by 558
Mathew, A., Fukuda, T., Nagaoka, Y., Hasumura, T., Morimoto, H., Yoshida, Y., Maekawa, T., Venugopal, K., & Kumar, D. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032616 · Cited by 454
Targeted nanoparticles for drug delivery through the blood–brain barrier for Alzheimer's disease
Roney, C. A., Kulkarni, P. V., Arora, V., Antich, P. P., Bonte, F. J., Wu, A., Mallikarjuana, N. N., Manohar, S. K., Liang, H., Kulkarni, A. R., et al. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.07.024 · Cited by 411
Chigurupati, S., Mughal, M. R., Okun, E., Das, S., Kumar, A., McCaffery, M. J., Seal, S., & Mattson, M. P. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.11.061 · Cited by 377
Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications
Rizzo, L. Y., Theek, B., Storm, G., Kiessling, F. M., & Lammers, T. (2013) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2013.02.020 · Cited by 348
Flagged first, then by citations
Cited by
Sorted by citations
Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease
Thawabteh, A. M., Ghanem, A. W., AbuMadi, S., Thaher, D., Jaghama, W., Karaman, D., & Karaman, R. (2024) · Molecules · doi:10.3390/molecules29215131 · Cited by 56
Metadata
- Authors
- Prajapati, V., Shinde, S., Shrivastav, P., & Prajapati, B. G.
- Affiliations
- Savitribai Phule Pune University (IN)
- Ganpat University (IN)
- Venue
- Alzheimer's Disease and Advanced Drug Delivery Strategies
- Publisher
- Elsevier
- Published
- 2024
- Pages
- 93-114
- OpenAlex
- W4390967514
- Cited by
- 7
- References
- 51
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 4
- FWCI
- 13.52
- Type
- book chapter
- Language
- en
- Open access
- closed
- Licence
- Locations
- Elsevier eBooks (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, biomaterials, biologicals, nanoparticles, metal nanoparticles, organic nanoparticles, cell therapy, dementia, drug delivery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
